As of Aug 26
| +0.01 / +0.18%|
The 3 analysts offering 12-month price forecasts for Juniper Pharmaceuticals Inc have a median target of 6.75, with a high estimate of 16.50 and a low estimate of 6.70. The median estimate represents a +18.21% increase from the last price of 5.71.
The current consensus among 3 polled investment analysts is to Hold stock in Juniper Pharmaceuticals Inc. This rating has held steady since August, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.